JP2010511022A5 - - Google Patents

Download PDF

Info

Publication number
JP2010511022A5
JP2010511022A5 JP2009538758A JP2009538758A JP2010511022A5 JP 2010511022 A5 JP2010511022 A5 JP 2010511022A5 JP 2009538758 A JP2009538758 A JP 2009538758A JP 2009538758 A JP2009538758 A JP 2009538758A JP 2010511022 A5 JP2010511022 A5 JP 2010511022A5
Authority
JP
Japan
Prior art keywords
vaccine
ccid
tetravalent
chimeri
den
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009538758A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010511022A (ja
JP5269803B2 (ja
Filing date
Publication date
Priority claimed from FR0655255A external-priority patent/FR2909286B1/fr
Application filed filed Critical
Publication of JP2010511022A publication Critical patent/JP2010511022A/ja
Publication of JP2010511022A5 publication Critical patent/JP2010511022A5/ja
Application granted granted Critical
Publication of JP5269803B2 publication Critical patent/JP5269803B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009538758A 2006-12-01 2007-11-30 デング熱の４種の血清型に対する免疫付与のプロトコル Expired - Fee Related JP5269803B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0655255A FR2909286B1 (fr) 2006-12-01 2006-12-01 Methode d'immunisation contre les 4 serotypes de la dengue
FR0655255 2006-12-01
PCT/FR2007/052431 WO2008065315A1 (fr) 2006-12-01 2007-11-30 Methode d'immunisation contre les 4 serotypes de la dengue

Publications (3)

Publication Number Publication Date
JP2010511022A JP2010511022A (ja) 2010-04-08
JP2010511022A5 true JP2010511022A5 (enExample) 2010-10-28
JP5269803B2 JP5269803B2 (ja) 2013-08-21

Family

ID=38198298

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009538758A Expired - Fee Related JP5269803B2 (ja) 2006-12-01 2007-11-30 デング熱の４種の血清型に対する免疫付与のプロトコル

Country Status (16)

Country Link
US (2) US7718359B2 (enExample)
EP (1) EP2099483B1 (enExample)
JP (1) JP5269803B2 (enExample)
KR (1) KR20090087890A (enExample)
CN (1) CN101541344A (enExample)
AR (1) AR064009A1 (enExample)
AU (1) AU2007327367B2 (enExample)
BR (1) BRPI0718927A2 (enExample)
CA (1) CA2668570A1 (enExample)
FR (1) FR2909286B1 (enExample)
IL (2) IL198466A (enExample)
MX (1) MX2009004223A (enExample)
MY (1) MY180698A (enExample)
TW (1) TWI400249B (enExample)
WO (1) WO2008065315A1 (enExample)
ZA (1) ZA200902540B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5227172B2 (ja) * 2005-08-10 2013-07-03 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー デングウイルス感染に対するワクチン接種
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
CN101959527B (zh) 2008-03-05 2016-04-20 赛诺菲巴斯德有限公司 一种使含佐剂的疫苗组合物稳定的方法
EP2143440A1 (fr) * 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
AU2010256845B2 (en) * 2009-06-01 2016-09-22 Takeda Vaccines, Inc. Compositions and methods for administration of vaccines against dengue virus
EP2473624B1 (en) * 2009-08-31 2019-05-01 Gen-Probe Incorporated Dengue virus assay
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
WO2012088041A1 (en) 2010-12-20 2012-06-28 Genvec, Inc. Adenoviral vector-based dengue fever vaccine
SG10201912291YA (en) 2012-07-24 2020-02-27 Sanofi Pasteur Vaccine compositions
AU2013295016A1 (en) 2012-07-24 2015-01-29 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
JP2016523251A (ja) * 2013-06-21 2016-08-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． デングウイルスワクチン組成物およびその使用方法
TWI852899B (zh) * 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
DK3197487T3 (da) 2014-09-26 2022-09-05 Seqirus Uk Ltd Vaccination af immunsvækkede individer
EP3316905A1 (en) 2015-07-03 2018-05-09 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
US10004795B2 (en) 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
WO2019069130A1 (en) 2017-10-05 2019-04-11 Sanofi Pasteur COMPOSITIONS FOR RECALL VACCINATION AGAINST DENGUE
EP3846849A1 (en) 2018-09-05 2021-07-14 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
BR112022001476A2 (pt) 2019-08-16 2023-10-03 Takeda Vaccines Inc Uso de uma vacina contra hepatite a e uma composição de vacina contra dengue ou uma dose unitária de uma composição de vacina contra dengue, combinação de vacina e kit
BR112022015710A2 (pt) 2020-02-27 2022-09-27 Takeda Vaccines Inc Método para remover dna de célula hospedeira a partir da preparação de vírus
EP4284426A1 (en) * 2021-01-28 2023-12-06 Vaccinvent GmbH Method and means for modulating b-cell mediated immune responses
WO2023147342A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
US20250177511A1 (en) 2022-02-15 2025-06-05 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
US20250342705A1 (en) 2022-05-04 2025-11-06 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity
WO2024108087A1 (en) 2022-11-18 2024-05-23 Takeda Vaccines, Inc. A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation
EP4626574A1 (en) 2022-11-29 2025-10-08 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2025072259A1 (en) 2023-09-25 2025-04-03 Takeda Vaccines, Inc. Coadministration of tetravalent dengue vaccine with hpv vaccine
WO2025122855A1 (en) 2023-12-08 2025-06-12 Takeda Vaccines, Inc. A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1080370A4 (en) 1998-05-29 2003-07-30 Epimmune Inc IDENTIFICATION OF RESILIENT DR EPITOPES LARGELY REACTIVE
US6537557B1 (en) 1999-03-26 2003-03-25 The United States Of America As Represented By The Secretary Of The Army Attenuated dengue-4 virus vaccine
EP1165127B1 (en) * 1999-03-26 2008-12-31 Walter Reed Army Institute of Research Multivalent dengue virus vaccine
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
ATE526411T1 (de) * 2000-02-16 2011-10-15 Us Gov Health & Human Serv Avirulente, immunogene flavivirus-chimäre
ATE412738T1 (de) * 2000-05-30 2008-11-15 Univ Mahidol Attenuierte stammen von denguevirus und ihre verwendungen in impfstoffzusammensetzungen
EP1159969A1 (fr) 2000-05-30 2001-12-05 Aventis Pasteur Vaccine composition
US20040259224A1 (en) 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
ES2345200T3 (es) 2003-03-24 2010-09-17 The Scripps Research Institute Vacunas de adn contra el crecimiento tumoral y procedimientos de utilizacion de las mismas.
CA2611954C (en) * 2005-06-17 2014-01-28 Sanofi Pasteur Dengue serotype 2 attenuated strain
CN101238144B (zh) * 2005-06-17 2012-09-05 赛诺菲巴斯德有限公司 登革血清型1减毒株
JP5227172B2 (ja) * 2005-08-10 2013-07-03 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー デングウイルス感染に対するワクチン接種
US7968102B2 (en) * 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
AR061197A1 (es) * 2006-06-07 2008-08-13 Sanofi Pasteur Cepas del virus 3 del dengue vivas atenuadas
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.

Similar Documents

Publication Publication Date Title
JP2010511022A5 (enExample)
JP2010505801A5 (enExample)
MX2009004223A (es) Protocolo de inmunizacion contra los 4 serotipos del dengue.
JP2015524421A5 (enExample)
WO2008022196A3 (en) Development of dengue virus vaccine components
JP2010521961A5 (enExample)
WO2010012069A8 (en) Multivalent vaccines based on papaya mosaic virus and uses thereof
JP2007538071A5 (enExample)
JP2008503716A5 (enExample)
BRPI0309631A8 (pt) vacina tetravalente da dengue contendo uma trivial deleção de 30 nucleotídeos na utr-31' dos tipos de dengue 1,2,3 e 4, ou de vírus antigênicos quiméricos da dengue 1,2,3 e 4
JP2009539965A5 (enExample)
AR063057A1 (es) Metodo de inmunizacion contra los 4 serotipos de dengue
EP2601969A3 (en) Norovirus vaccine formulations
JP2009504654A5 (enExample)
BRPI0908489A2 (pt) uso de compostos químicos e método para desenhar compostos químicos que atenuam ou inibem a infecção pelo vírus da dengue
CY1114298T1 (el) Διαμορφωτικως περιορισμενα διφαινυλ παραγωγα για χρηση ως αναστολεις ιου ηπατιτιδας c
JP2007538072A5 (enExample)
JP2011051997A5 (enExample)
NZ597000A (en) Compositions and methods for administration of vaccines against dengue virus
WO2010025109A8 (en) Vaccine against highly pathogenic porcine reproductive and respiratory syndrome (hp prrs)
JP2010500398A5 (enExample)
JP2017526689A5 (enExample)
CA2915027A1 (en) Compositions and methods for administration of vaccines against dengue virus
JP2013542981A5 (enExample)
JP2008531742A5 (enExample)